| Abstract |
Objective To observe the therapeutic value of Shenyan Kangfu tablets combined with Benazepril in the treatment of diabetic nephropathy, and look forward to applying all the research results to practice to provide valuable theoretical reference and practical basis for clinical practice. Methods The selected samples were all diabetic nephropathy patients admitted to our hospital, with a total of 100 cases. The duration of the experiment was from November 2022 to November 2023. According to the order of admission, 50 patients were divided into one group, named the reference group, and the Benazepril treatment regimen was implemented. The other 55 patients were divided into one group, named as the study group, and the treatment regimen of Benazepril combined with nephritis rehabilitation tablets was implemented. Then, relevant data were collected and sorted, and statistical methods were used for comparison and analysis, including clinical efficacy, renal function indicators, oxidative stress indicators, endothelial function, and incidence of adverse reactions. Results Compared between groups, compared with treatment plans, patients in the study group were significantly better than those in the reference group (P < 0.05) in the embodiment of various index values, which had comparable value and was worth exploring. Conclusion In this experiment, the application effect of Shenyan Kangfu tablet combined with benazepril in the treatment of diabetic nephropathy was analyzed and discussed in a targeted way, aiming to seek a feasible treatment plan through comparison to effectively inhibit the progression of diabetic nephropathy patients, and the outcome was clear. The combined application of Shenyan Kangfu tablet and Benazepril could not only effectively improve the clinical efficacy, but also improve the clinical efficacy. And greatly reduce the probability of adverse reactions, its application value is excellent, far-reaching promotion significance, worthy of adoption.
|